PREVALENCE AND CORRELATION OF CONTRACEPTIVE USE AMONG FEMALES IN JEDDAH, SAUDI ARABIA

  • ALAA BAGALAGEL Pharmacy Practice Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia

Abstract

Objective: The purpose of this study was to examine the prevalence of contraceptive use and the correlates of contraceptive use among females in Jeddah, Saudi Arabia. Moreover, it aimed to evaluate the knowledge about contraceptives and their use.


Methods: The study was a community-based, cross-sectional descriptive survey conducted in Saudi Arabia from 28 September 2015 to 10 December 2015.


Results: The current study showed that the most commonly used contraceptives were intrauterine devices (IUD’s) (29.1%), followed by male condoms (27.7%). Most of the participants, 47.6%, started using a contraceptive after giving birth to their first child. Nearby, 60% of participants used contraceptives without a prescription or medical advice. Only 13.7 % of participants sought the advice of a pharmacist about which contraceptive they should use, while 30.6% and 24.2% of participants choose their contraceptive based on general knowledge and relatives’ experiences, respectively. Around 80% of participants stated that they did not have any problem while buying contraceptives from pharmacies without a prescription.


Conclusion: Pharmacists and medical health providers need to fill this gap to improve the use of contraceptives.

Keywords: Contraceptives, Prevalence, Saudi Arabia

Downloads

Download data is not yet available.

References

1. Lutalo T, Musoke R, Kong X, Makumbi F, Serwadda D, Nalugoda F. Effects of hormonal contraceptive use on HIV acquisition and transmission among HIV-discordant couples. AIDS 2013;1:27–34.
2. Westhoff C. A highly effective contraceptive option with proven long-term safety. Contraception 2003;68:75–87.
3. Segall Gutierrez P, Taylor D, Liu X, Stanzcyk F, Azen S, Mishell Jr. Follicular development and ovulation in extremely obese women receiving depo medroxyprogesterone acetate subcutaneously. Contraception 2010;81:487–95.
4. de Morais TL, Giribela C, Nisenbaum MG, Guerra G, Mello N, Baracat E, et al. Food and drug administration office of surveillance and epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints 2011;342:2151-6.
5. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011;183:E1319-E1325.
6. Stegeman BH, de Bastos M, Rosendaal FR. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. Br Med J 2013;347:5298.
7. Mohllajee AP, Curtis KM, Flanagan RG, Rinehart W, Gaffield ME, Peterson HB. Keeping up with evidence a new system for WHO's evidence-based family planning guidance. Am J Prev Med 2005;28:483–90.
8. Felix AS, Gaudet MM, Vecchia CL. Intrauterine devices and endometrial cancer risk: a pooled analysis of the epidemiology of endometrial cancer consortium. Int J Cancer 2015;136:E410-22.
9. Hussainy SY, Ghosh A, Taft A, Mazza D, Black KI, Clifford R, et al. Protocol for ACCESS: a qualitative study was exploring barriers and facilitators to accessing the emergency contraceptive pill from community pharmacies in Australia. Br Med J Open 2014;89:31–5.
10. Hatcher RA, Trussell J, Nelson AL. Contraceptive technology. New York: Ardent Media; 2007;80:87–116.
11. Thapa S. A new wave in the quiet revolution in contraceptive use in Nepal: the rise of emergency contraception. Reprod Health 2016;13:49.
12. Jensen JT. Vaginal ring delivery of selective progesterone receptor modulators for contraception. Contraception 2013;87:314-8.
13. Mubyazi GM, Exavery A, Tenu F, Massaga JJ, Rugemalila J, Malebo HM, et al. Determinants of demand for condoms to prevent HIV infections among barmaids and guesthouse workers in two districts, Tanzania. BMC Res Notes 2015;8:630.
14. Wiegratz I, Bassol S, Weisberg E, Mellinger U, Merz M. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety. Reprod Sci 2014;21:1518–25.
15. Hohmann H. Examining the efficacy, safety, and patient acceptability of the etonogestrel implantable contraceptive. Patient Prefer Adherence 2009;3:205–11.
16. Ghofrani HA, Galie N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330–40.
17. Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000;355:2133-4.
18. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V leiden mutation. Lancet 1994;344:1453-7.
19. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women a case-control study. Int J Epidemiol 1992;21:48-52.
20. Farley TM, Meirik O. Effect of different progestogens in low estrogen oral contraceptives on the venous thromboembolic disease. Lancet 1995;346:1582–8.
21. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera®): a highly effective contraceptive option with proven long-term safety. Contraception 2003;68:75–87.
22. Shukla A, Jamwal R, Bala K. Adverse effect of combined oral contraceptive pills. Asian J Pharm Clin Res 2017;10:17-21.
23. Halpern V, Combes SL, Dorflinger LJ, Weiner DH. Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. Contraception 2014;89:31–5.
24. Planas ME, García PJ, Bustelo M, Carcamo CP, Martinez S, Nopo H, et al. Effects of ethnic attributes on the quality of family planning services in lima, peru: a randomized crossover trial. PLOS One 2015;10:121–57.
25. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merliere Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010;58:286-90.
26. Potter FJ, Iannacchione VG, Mosher WD, Mason RE, Kavee JD. Sample design, sampling weights, imputation, and variance estimation. National Center for Health Statistics. Vital Health Stat 1998;2:1-63.
27. Mosher WD, Jones J. Use of contraception in the world. National Center for Health Statistics. Vital Health Stat 2010;23:554-5.
28. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States. Perspect Sex Reprod Health 2006;38:90-6.
29. Finer LB, Zolna MR. Unintended pregnancy in the United States: Incidence and disparities. Contraception 2011;84:478-85.
30. Chandra A. Health aspects of pregnancy and childbirth: United States, 1982–1988. Vital Health Stat Series 23, Data From the National Survey of Family Growth; 1995. p. 1-74.
31. Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the national survey of family growth. Contraception 2008;77:10-21.
32. Fisher WA, Black A. Contraception in canada: a review of method choices, characteristics, adherence and approaches to counselling. CMAJ 2007;176:953-61.
33. Black A, Yang Q, Wen SW. Contraceptive use among canadian women of reproductive age: results of a national survey. J Obstet Gynaecol Can 2012;31:627-40.
34. Rotermann M, Sanmartin C, Hennessy D. Prescription medication use by canadians aged 6 to 79. Health Rep 2014;25:3-9.
35. Siedlecky S. Patterns of contraceptive use in canada: an analysis of 2014 national health survey. J Biosocial Sci 2012;39:735-44.
36. Reid RL. Non-contraceptive uses of hormonal contraceptives. Obstet Gynecol 2010;115:206-18.
37. Alateeg FA. Use of contraceptive among women: Natural family planning revisited. Saudi Med J 2013;25:285-93.
38. Al-turki HA. Contraception: attiudes and experiences of Saudi Arabian Women. Health Care Women Int 2011;32:134-9.
39. Abdul Salam A. Nuptiality and fertility in Saudi Arabia: an appraisal of census data. Middle East Fertility Soc J 2013;18:147-53.
40. Almukhtar R. SR108 million spent on birth control pills. Arab News; 2014.
41. Thorogood M. Contraceptives and myocardial infarction: new evidence leaves unanswered questions. Thromb Haemost 1997;78:334-8.
42. Schwartz SM, Petitti DB, Siscovick DS, Longstreth Jr WT, Sidney S, Raghunathan TE, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two us studies. Stroke 1998;29:2277-84.
43. Sidney S, Siscovick DS, Petitti DB. Myocardial infarction and use of contraceptives: a pooled analysis of two canadian studies. Circulation 2011;98:1058-63.
44. Petitti DB, Sidney S, Bernstein A. Stroke in users of contraceptives. N Engl J Med 2011;335:8-15.
45. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397–404.
46. Lepkowski JM, Mosher WD, Groves RM, Van Hoewyk J. The 2010 national survey of family growth: sample design and analysis of a continuous survey. Vital Health Stat 2010;2:1-36.
47. Shakhatreh FM. Contraceptive use in Saudi Arabia. Med J 20;22:512-5.
48. Trussell J. Estimates of contraceptive failure from the 2010 national survey of family growth. Contraception 2011;78:85-6.
49. Goldscheider C, Mosher WD. Religious affiliation and contraceptive usage: Changing American pattern. Stud Fam Plann 2011;19:48–57.
50. Collaborative group on epidemiological studies of ovarian cancer. Ovarian cancer and contraceptives. Lancet 2010;371:303-14.
51. Al Riyami AA, Afifi M. Determinants of women's fertility in Saudi Arabia. Saudi Med J 2011;24:748-53.
52. Chuang CH, Hwang SW, McCall-Hosenfeld JS. Primary care physicians’ perceptions of barriers to preventive reproductive health care in rural communities. Perspect Sex Reprod Health 2012;44:78–83.
53. Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U. S. women: data from the 2011 national survey of family growth. National Center for Health Statistics. Vital Health Stat 2 2011;23:45-6.
54. Charleton BM, Colditz GA. Oral contraceptive use and mortality after 36 y of follow-up in the Nurses’ Health Study: Prospective cohort study. Br Med J 2014;349:441-3.
55. Alsheeha M. Awareness and use of contraceptive among Saudi Women attending primary care centers in al-qassim, Saudi Arabia. Int J Health Sci (Qassim) 2010;4:11–21.
56. Petitti DA, Sidney S, Quesenberry CP. Contraceptive use and myocardial infarction. Contraception 2012;57:143-55.
57. Chasan Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 2011;128:467-77.
58. Farmer RD, Lawrenson RA, Thompson CR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.
59. Jick H, Jick SS, Gurewich V. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using contraceptives with differing progestagen components. Lancet 2012;346:1589-93.
60. Alateeg FA. Natural family planning revisited. Saudi Med J 2011;25:285-93.
61. Heinemann L, Spitzer WO. The use of contraceptives and the occurrence of acute myocardial infarction in young women: results from the transnational study on oral contraceptives and the health of young women. Contraception 2011;56:129-40.
62. Lidegaard O. Smoking and use of contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol 1999;180:S357-63.
63. Carr BR, Ory H. Estrogen and progestin components of contraceptives: relationship to vascular disease. Contraception 2011;55:267-72.
64. Haapaniemi H, Hillbom M, Juvela S. Lifestyle-associated risk factors for acute brain infarction among persons of working age. Stroke 2012;28:26-30.
65. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 2006;103:535-40.
66. Curtin SC, Abma JC, Ventura SJ, Henshaw S. Impact of social franchising on contraceptive use when complemented by vouchers a quasi-experimental study. PLOS One 2013;8:345-7.
67. Secura GM, Madden T, McNicholas C. Provision of no-cost, long-acting contraception and teenage pregnancy. N Engl J Med 2014;371:1316-23.
68. Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The contraceptive choice project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol 2013;203:115–7.
69. Wang C. History of the Indonesian family planning program. Contraception 2010;85:563–9.
70. Casey SE, Mitchell KT, Amisi I, Haliza MM, Aveled B, Kalenga P. Use of facility assessment data to improve reproductive health service delivery in the democratic republic of the congo. Confl Health 2011;3:12-4.
71. Jain A, Bruce J, Mensch B. Setting standards of quality in family planning programs. Stud Fam Plann 2014;23:392–5.
Statistics
76 Views | 80 Downloads
Citatons
How to Cite
BAGALAGEL, A. “PREVALENCE AND CORRELATION OF CONTRACEPTIVE USE AMONG FEMALES IN JEDDAH, SAUDI ARABIA”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, no. 8, June 2020, pp. 149-55, doi:10.22159/ijpps.2020v12i8.38100.
Section
Original Article(s)